Fonseca, Elena http://orcid.org/0000-0002-3895-1237
Sarria-Estrada, Silvana
Pareto, Deborah http://orcid.org/0000-0001-7356-3769
Turon, Marc
Quintana, Manuel
Santamarina, Estevo
Abraira, Laura
Tortajada, Carlos
Rovira, Àlex
Toledo, Manuel
Funding for this research was provided by:
Fundación Tatiana Pérez de Guzmán el Bueno (Beca predoctoral en neurociencias 2019)
Article History
Accepted: 18 October 2022
First Online: 10 November 2022
Declarations
:
: E. Fonseca declares research funding and honoraria from UCB Pharma, Esteve laboratorios, Eisai Inc, GW Pharmaceuticals, Angelini Pharma and Sanofi Genzyme. E. Santamarina declares research funding and speaking fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc. and Esteve laboratorios. L. Abraira declares research funding and speaking fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc., Sanofi Genzyme and Esteve laboratorios. I. Seijo declares research funding from UCB Pharma, Neuraxpharm and GW pharmaceuticals. M. Toledo declares research funding and speaking fees from UCB Pharma, BIAL Pharmaceutical, EISAI Inc., GW Pharmaceuticals, Arvelle Therapeutics, Angelini Pharma and Esteve laboratorios. S. Sarria, D. Pareto, M. Turon, M. Quintana, C. Tortajada and A. Rovira have no conflicts of interest to declare.
: We confirm that we have read the journal’s position on issues concerning ethical publication and that this report is consistent with those guidelines. The study protocol was approved by the Vall d’Hebron Research Institute Ethics Committee [PR(AG)391/2017], following the Ethics of the World Medical Association for experiments involving humans. The study conforms with the STROBE guidelines for observational studies.
: All patients provided signed written informed consent prior to inclusion in the study.
: Not applicable.